Low back pain

Aclarion’s Nociscan Solution to Play Key Role in Groundbreaking LIFEHAB Trial Evaluating the Diagnosis and Treatment of Chronic Low Back Pain

Retrieved on: 
Jeudi, avril 25, 2024
CO, Pain, ACON, Randomized controlled trial, Oslo University Hospital, Haukeland University Hospital, Software as a service, Low back pain, Biomarker, Patient, Physician, Diagnosis, Clinical trial, Algorithm, Akershus University Hospital

BROOMFIELD, CO, April 25, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW),a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that the Nociscan solution will be utilized in the upcoming LIFEHAB Trial in Norway. The randomized controlled trial studying 202 patients with low back pain greater than 1 year in duration will compare treatment outcomes between lumbar interbody fusion surgery and multidisciplinary rehabilitation.

Key Points: 
  • “Diagnosing the source of chronic low back pain is  a significant challenge for clinicians,” said Dr. Ansgar Espeland.
  • “At Haukeland University Hospital, our radiology team has participated in numerous clinical trials seeking to better understand the linkage between the diagnosis and treatment of chronic low back pain.
  • The LIFEHAB Trial is our latest effort to advance scientific understanding of chronic low back pain.
  • The LIFEHAB trial represents the fourth important trial since 2021 to utilize Nociscan, a testament to our growing body of evidence and the relative distinction of the Nociscan solution.”
    For more information on the LIFEHAB Trial: https://classic.clinicaltrials.gov/ct2/show/NCT06169488

Elon Musk says ‘disc replacement’ worked for him. But evidence this surgery helps chronic pain is lacking

Retrieved on: 
Mardi, avril 23, 2024
Uncertainty, Chronic pain, Biography, Exercise, Infection, Patient, Research, Neck pain, Spinal fusion, Low back pain, Surgeon, Leg, Clinical trial, Back pain, Fracture, Ketamine, Spine, Pain, Elon Musk, Musk, Movement, Neck, Dentistry

In comments following the post, Musk said the surgery was a “gamechanger” and reduced his pain significantly.

Key Points: 
  • In comments following the post, Musk said the surgery was a “gamechanger” and reduced his pain significantly.
  • So what is disc replacement surgery and what does the evidence tells us about its benefits and harms?

What’s involved in a disc replacement?

  • Disc replacement may be performed for a number of reasons, including slipped discs in the neck, as appears to be the case for Musk.
  • In Australia, even if you have health insurance, a disc replacement surgery may leave you more than A$12,000 out of pocket.
  • Disc replacement surgery is not performed as much as other spinal surgeries (for example, spinal fusion) but its use is increasing.
  • In New South Wales for example, rates of privately-funded disc replacement increased six-fold from 6.2 per million people in 2010–11 to 38.4 per million in 2019–20.

What are the benefits and harms?

  • But there has been very little research comparing disc replacement surgery with non-surgical treatments.
  • Unfortunately, these crucial first research steps have largely been skipped for disc replacement surgery for both neck and back pain.
  • There are no clinical trials we know of investigating whether disc replacement is effective for neck pain compared to nothing or compared to non-surgical treatments.
  • Complications are not uncommon, and can include disclocation of the artificial disc, fracture (break) of the artificial disc, and infection.
  • Revision surgery means a re-do to the primary surgery if something needs fixing.

Are there effective alternatives?

  • Many surgeons see disc replacement as an alternative to spinal fusion, and this choice is often presented to patients.
  • Indeed, the research evidence used to support disc replacement mainly comes from studies that compare disc replacement to spinal fusion.
  • Fortunately for patients, there are new, non-surgical treatments for neck and back pain that evidence is showing are effective – and are far cheaper than surgery.
  • Christine Lin receives funding from the National Health and Medical Research Council (NHMRC), and Medical Research Future Fund.
  • Christopher Maher receives funding from the National Health and Medical Research Council (NHMRC), and Medical Research Future Fund.

Insights into the Future of Neurology Devices: Exploring the Global Market Report by BCC Research

Retrieved on: 
Jeudi, mars 28, 2024
Epilepsy, Organization, MRI, Prevalence, Brain, Multiple sclerosis, Data analysis, Neuro, Alzheimer's disease, Nervous system, Patient, Radiosurgery, Research, Spinal cord stimulator, Electrode, Parkinson's disease, Low back pain, Investment, DSM-IV codes, Neurosurgery, Population growth, Ageing, Medical imaging

BOSTON, March 28, 2024 /PRNewswire/ -- According to the latest research study, the demand for Neurology Devices: Global Markets expected to grow from $23.7 billion in 2023 to $31.7 billion by the end of 2028 at a compound annual growth rate (CAGR) of  6.0% from 2023 through 2028.

Key Points: 
  • Neurology Devices: Global Markets is basically a detailed study or report about the worldwide market for medical tools used in treating neurological conditions.
  • The report looks at things like how much these devices are used, where they're used, and how the market for them is growing.
  • This report thoroughly examines the global market for neurology devices, categorizing it by product type and region.
  • Non-surgeons are increasingly performing spinal cord stimulation procedures instead of neurosurgeons due to the rising global burden of low back pain.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Mardi, mars 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Digital Health in the Neurology Market worth $167.58 Bn by 2031 - Exclusive Report by InsightAce Analytic Pvt. Ltd.

Retrieved on: 
Mardi, mars 19, 2024
Health, Brain, Growth, Neurology, Multiple sclerosis, Deficit spending, Seizure, Rehabilitation, Partnership, Patient, Kernel, Internet, Research, Artificial intelligence, Acquisition, Parkinson's disease, Low back pain, Biogen, KMDF, Neurological disorder, DSM-IV codes, Intellectual property, Government, Report, Virtual reality, Medicine, Pharmaceutical industry

There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.

Key Points: 
  • There are strict regulatory frameworks in place in several locations that affect the digital health sector of neurology.
  • While these rules are essential for protecting patients' health, they can hinder the development and rollout of innovative digital health solutions in neurology.
  • These limitations are expected to limit the expansion of the digital health market in neurology during the next few years.
  • The North American digital health in neurology market is expected to register a large market share in the revenue.

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Retrieved on: 
Jeudi, mars 7, 2024
Modic, Safety, Disability, Pharmacokinetics, Patient, Pain, Medication, Psychotherapy, Low back pain, Genetically modified bacteria, Pharmaceutical industry

Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain

Key Points: 
  • Persica Pharmaceuticals completes recruitment into Modic Trial assessing efficacy of PP353, to treat chronic lower back pain
    London, UK, 07 March 2024 – Persica Pharmaceuticals Ltd, a privately held, clinical stage pharmaceutical company developing an antibiotic formulation for intradiscal injection to treat Chronic Low Back Pain (CLBP) and disability associated with bone oedema (Modic 1), which is caused by bacterial infection, today announces the completion of enrolment of participants into its Phase 1b Modic Trial.
  • CLBP is a leading cause of disability with significant unmet medical need and contributes to the overuse of chronic opioid therapy.
  • The Modic Trial is a placebo-controlled randomised clinical trial assessing the safety and efficacy of PP353 as a treatment for patients with CLBP associated with Modic 1 changes.
  • Dr Steve Ruston, Chief Executive Officer of Persica Pharmaceuticals Ltd, said: “CLBP is a debilitating condition which affects millions of people.

Aclarion Announces Publication of Compelling Peer-Reviewed Data in International Journal of Spine Surgery Supporting Nociscan as a Gold Standard for Noninvasive Identification of Painful Lumbar Discs

Retrieved on: 
Lundi, mars 4, 2024
Paper, Comparison, Algorithm, PD, ACON, Gold standard, Physician, Pain, Surgeon, Discography, International Society, Biomarker, Software as a service, CLARITY, Patient, Canadian International Council, Diagnosis, Low back pain, CO, Research, Medical imaging

BROOMFIELD, CO, March 04, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire -- Aclarion, Inc., (“Aclarion” or the “Company”) (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today the publication of the clinical paper, Establishing a Gold Standard for Noninvasive Identification of Painful Lumbar Discs: Prospective Comparison of Magnetic Resonance Spectroscopy vs Low-Pressure Provocation Discography by the International Journal of Spine Surgery, the official scientific journal of the International Society for the Advancement of Spine Surgery (ISASS).

Key Points: 
  • Nociscan demonstrated a sensitivity of 100% and a specificity of 80% compared to provocative discography (PD), suggesting Nociscan provides better information to surgeons.
  • Low-pressure provocative discography (PD) has served as the gold standard, despite well-documented drawbacks including being highly invasive and presenting difficult-to-interpret results.
  • Achieving a result of 100% sensitivity (5/5 lumbar discs) means that in this study if discography indicates a disc is painful, then Nociscan will also indicate that the disc is painful.
  • We look forward to introducing Nociscan to a growing number of physicians and patients.”
    Access to the publication can be found here.

Filtering The Facts: The Urology Care Foundation Spreads Awareness for National Kidney Month

Retrieved on: 
Vendredi, mars 1, 2024
Urination, Diabetes, Fever, Woman, Anemia, Penis, Workplace, Kidney, Blood, Smoking, Mineral, Hormone, Pain, Weight loss, Infection, Rib, Nausea, Vomiting, Human, Kidney cancer, University, Somatic symptom disorder, AUA, Tobacco, Disease, Urine, Risk factor, Low back pain, Risk, American Urological Association, Salt, Water, Phosphorus

BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.

Key Points: 
  • BALTIMORE, March 01, 2024 (GLOBE NEWSWIRE) -- March is National Kidney Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to help share all the tools and information you need to take charge of your kidney health.
  • The kidneys also make hormones that help to keep blood pressure stable, make red blood cells and help keep bones strong.
  • Kidney health deserves equal awareness,” said Dr. Timothy Averch, chair of the Urology Care Foundation’s Kidney and Adrenal Health Committee.
  • For National Kidney Month, the Urology Care Foundation is focusing on information about kidney cancer and kidney stones:
    It is estimated that there will be over 81,000 new kidney cancer cases and over 14,000 cancer deaths in the United States in 2024.

EmergeOrtho--Triangle Region Welcomes Dr. Ryan McCarter

Retrieved on: 
Lundi, mars 4, 2024
Neck pain, Spine, Quality of life, Raleigh, North Carolina, Fluoroscopy, Rehabilitation, Patient, Spinal stenosis, Physiology, Low back pain, Sports medicine, MRI, Nursing

DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.

Key Points: 
  • DURHAM, N.C., March 4, 2024 /PRNewswire/ -- EmergeOrtho—Triangle Region welcomes Dr. Ryan McCarter, a highly esteemed Physical Medicine and Rehabilitation specialist, focusing on Interventional Spine and Musculoskeletal Medicine.
  • "I'm excited to join the EmergeOrtho team and contribute to the mission of delivering top-tier orthopedic and musculoskeletal care," said Dr. McCarter.
  • "As a physician, my goal is to empower each patient on their journey to recovery," said Dr. McCarter.
  • To seek pain treatment, schedule an appointment with Dr. Ryan McCarter.

Urology Care Foundation Spreads Awareness for National Cancer Prevention Month

Retrieved on: 
Mercredi, janvier 31, 2024
Education, Ache, Penile cancer, Urethral cancer, Urination, Kidney cancer, Bleeding, Fluid mechanics, Testicular cancer, Heredity, Urethra, Radiation, Back pain, Infection, Bladder cancer, Abdomen, Foreskin, Weight loss, FACS, Fever, Groin, Risk factor, Diet, AUA, Blog, Cancer, HPV, Combustion, Woman, Urethral caruncle, Growth, Papillomaviridae, Prostate cancer, Low back pain, Penis, Urethral diverticulum, Rib, Death, Skin, Blood, Disease, AIDS, Risk, Ejaculation, Smoking, Workplace, UTI, American Urological Association, Male, Scrotum, Pain, Tenderness, MBA, Somatic symptom disorder, Urine, Smoker, GCNIS, Ulcer, Birth control

BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.

Key Points: 
  • BALTIMORE, Jan. 31, 2024 (GLOBE NEWSWIRE) -- February is National Cancer Prevention Month, and the Urology Care Foundation, the official foundation of the American Urological Association (AUA), wants to spread awareness and information on the six main urologic cancers.
  • However, there are other urologic cancers that involve the bladder, kidneys and testicles,” said Urology Care Foundation Board of Directors member Brian McNeil, MD, MBA, FACS.
  • The Urology Care Foundation believes the first part of prevention is education.
  • Below are the six main urologic cancers and important resources for each:
    Bladder Cancer is the second most common type of urologic cancer.